Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Expenses (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Accumulated Expenses for 11 consecutive years, with $26.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 2.76% year-over-year to $26.9 million, compared with a TTM value of $26.9 million through Dec 2025, down 2.76%, and an annual FY2025 reading of $26.9 million, down 2.76% over the prior year.
  • Accumulated Expenses was $26.9 million for Q4 2025 at Spyre Therapeutics, up from $23.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $27.7 million in Q4 2024 and bottomed at $2.4 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $13.4 million, with a median of $13.0 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 1652.16% in 2021, then crashed 78.19% in 2022.
  • Year by year, Accumulated Expenses stood at $14.0 million in 2021, then decreased by 8.5% to $12.8 million in 2022, then rose by 2.11% to $13.1 million in 2023, then skyrocketed by 111.41% to $27.7 million in 2024, then fell by 2.76% to $26.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for SYRE at $26.9 million in Q4 2025, $23.8 million in Q3 2025, and $19.4 million in Q2 2025.